ClinicalTrials.gg
Sign In
TerminatedNCT02021487Prok-IdmUpdated Aug 21, 2019

Prokinecitine in Acute Myocardial Infarction

An observational study in ST Elevatation Myocardial Infarction (STEMI), sponsored by University Hospital, Strasbourg, France. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-21.

Sponsored by University Hospital, Strasbourg, France · Observational

Why this study was terminated
recruitment difficulty
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
172
Ages
18 Years and older
Sex
All
01

Study summary

The study aims to investigate the presence of a substance in the blood called prokinecitine, which is released by the heart when a heart attack occurs. Several venous blood samples at the arm are withdrawn at admission, H6, H12, H24, H48 and H72 in order to measure the concentration of this substance in the blood. The usefulness of this new blood marker is going to be determsined to seek if it would be of help to better diagnose or estimate the gravity of heart infarction after a heart attack.

02

Conditions studied

  • ST Elevatation Myocardial Infarction (STEMI)
03

In context

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 994 studies on the registry; 353 are open to participants now.

Browse University Hospital, Strasbourg, France studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with acute St elevation myocardial infarction of less than 6 hours

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with acute St elevation myocardial infarction of less than 6 hours
  • Age>18 y/o

Exclusion criteria

Exclusion Criteria:

  • Previous myocardial infarction
  • LBB, RBB
  • Renal Insuffiency MDRD\<30 mL/min
  • Patient with Pace-Maker or ICD.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
172 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Infarct size by MRI necrotic myocardial mass

    Infarct size by MRI necrotic myocardial mass

    Time frame: 7 days

07

Study locations

1 site
  • University Hospital
    Strasbourg, 67000, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2013 to primary completion in Feb 2019, 63 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2013
First posted
Dec 27, 2013
StartActual
Nov 2013
Primary completionActual
Feb 2019
CompletionActual
Feb 2019
Last update
Aug 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02021487
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Dec 27, 2013
Start date
Nov 2013
Primary completion
Feb 2019
Completion
Feb 2019
Last update
Aug 21, 2019

Study contacts

Patrick OHLMANN, MD
principal investigator · University Hospital, Strasbourg, France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

University Hospital, Strasbourg, France →

Start the discussion